R3HCC1L

Across TCGA pan-cancer cohorts, R3HCC1L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of R3HCC1L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where R3HCC1L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types R3HCC1L is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where R3HCC1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in R3HCC1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.308	<.001	10	view →
LUAD	Female	All	−0.256	<.001	9	view →
HNSC	Male	III,IV	−0.391	<.001	8	view →
LSCC	All	All	−0.069	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

R3HCC1L–CCRCC

Open the CCRCC breakdown →